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Levels in serum of components of complement were 
studied in a group of 10 patients with mixed cryoglobu-
linemia. The profiles found in most patients showed 
decreased levels of the early complement components 
Cl, C4, and C2, with normal levels of C3. Experiments 
performed to d efine the mechanism(s) responsible for 
this unusual complement profile showed that activation 
of the early complement components in serum was due 
to the activation of the classical pathway· by mixed cry-
oglobulins. They also showed that the characteristic lack 
of effect on C3 was due to the action of a previously 
unrecognized regulatory mechanism upon C3 convertase 
of the classical pathway mediated by 2 normal serum 
proteins, namely, the C4 binding protein (C4-bp) and the 
C3b inactivator (C3biNA). 
Cryoglobulins are an abnormal group of serum proteins which 
share the common property of reversible precipitation at low 
temperatures [1]. It is now accepted that the majority of cry-
oglobulins are either intact monoclonal immunoglobulins (lgs) 
[2], or more often, Ig complexes in which one component, 
usually IgM, exhibi ts antibody activity to lgG [3-5]. These 
latter complexes have been termed mixed cryoglobulins. 
Cryoimmunoglobulinemia, as a syndrome, has been associ-
ated with a diverse group of hematopoietic malignancies, acute 
and chronic bacterial infections, and collagen-vascular diseases. 
Moreover, there is an essential form [6,7]. R ecently, however, 
it has been recognized that viral infections, most commonly the 
one of hepatitis B virus, appear to be involved in the pathogen-
esis of the essential form [8]. 
T he most important clinical features of this general synd1·ome 
are purpura, which is present in most patients, arthralgias, 
weakness, and renal involvement that can be rapidly progres-
sive [5]. Histologic examination of the affected tissues shows 
vascular lesions compatible with leukocytoclastic vasculitis. 
Although these vascular lesions are most frequently seen in the 
skin, they are also found to a lesser extent in other organs such 
as the kidneys, heart, brain, and pancreas [9). The cause of this 
vasculitis is unknown. However, it has been suggested that 
mixed cryoglobulins may function as immune-complexes, and 
that their deposition in tissues may cause subsequent vascular 
inflammation. The demonstration of IgG, l gM, and deposits of 
components of complement at involved sites, lends support to 
this hypothesis [5,10,11]. 
Determinations of complement-component levels in the sera 
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Abbreviations: 
C3blNA: C3b inactivator 
C4-bp: C4 binding protein; 
C42: classical pathway convertase; 
OTT: DL-dithiothreito l; 
0-GVB++ : half-isotonic Veronal-buffered saline, 0.1% gelatin, 0.5 
mM magnesium, 0.15 mM calcium, and 2.5% dextrose 
SDS: sodium dodecyl sulfate 
of patients with essential mixed cryoglobulinemia have gener-
ally revealed low levels of C1, C4, and C2, with no effect on C3 
levels in most cases [12-14]. There are, h owever, rare reports of 
low levels of C3 and CH5o [15,16]. It has been hypothesized th at 
the lack of C3 activation, in spite of markedly decreased levels 
of C4 and C2, is due to hyposynthesis of these early complement 
components, rather than a consequence of complement activa-
tion [13,17]. Here we present evidence that the lack of effect 
upon C3 may be due to a previously undescribed reroJlatory 
mechanism of the classical pathway C3 convertase (Cll2 ), me-
diated by two normal serum proteins: the C4 binding protein 
(C4-bp) and the C3b inactivator (C3biNA) [18]. 
MATERIALS AND METHODS 
Buffers 
Veronal-buffered saline 0.15 M, pH7.5, containing 0.1% gelatin 
(GVB- ), 0.15 mM CaCb and 0.5 mM MgCb (GVB++ ); dextrose-veronal-
buffered saline 0.075 M (0-GVB++) and 0.04 M disodium ethylenedi-
aminetetracetate (EDTA) buffer in GVB- (EDTA GVB- ) were pre-
pared as previously described [19). 
Purified Complement Components, Cellular Intermediates and 
Assays 
Guinea pig [19] and human CI [20], human C4 [21], C2 [22], C3 
[23], C4-bp [24], and C3blNA [25,26] were purified by previously 
published techniques. C4 was rad iolabeled with 1201 by the lactoperox-
idase method [27]: the specific activity was == 3 X 105 cpm/i.tg protein. 
EA and EACI cells were prepared from sheep erythrocytes as previ-
ously described and were converted to EAC14 cells using highly purified 
C4 at a concentrat ion of 6 !J.g/1 X 10~ cells [28]. Measurements of C4, 
C2, and C3 were performed by hemolytic t itrations [29). Rat serum, 
diluted 1/20 in EDTA GVB- , was used as a source of C3-C9. The C5, 
C6, C7, C8, and C9 used in C3 tit rations were purchased from Cordis 
Laboratories (Miami, Florida). 
Depletion of C4- bp from Normal Human Serum 
Rabbit ant i-C4-bp was prepared by injecting rabbi ts with pUl'ified 
C4-bp incorporated in complete Freund's adjuvant. By cross immuno-
electrophoresis the antiserum reacted against a single protein in human 
serum and against purified C4-bp. The lgG fraction of this ant iserum, 
obta ined by DEAE-cellulose chromatography, was coupled to CNBr-
activated Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, N ew 
Jersey) fo llowing directions from the manufacturer. 
Serum depleted of C4 -bp was obtained by passage of 2 ml of fresh 
normal human serum containing 0.02 M EDTA through an anti-C4-bp 
immunoabsorbent column equilibrated with EDTA GVB- . The efflu ent 
was concentrated to the original serum volume by ultraftltration. 
Structural Analysis of Bound 125J-C4 
Polyacrylamide slab gel electrophoresis (SDS-PAGE) was performed 
as described by Laemmli [30]. Cryoglobulins canying 120I-C4 were 
solubilized in a buffer containing 0.0625 M Tris-HCl pH6.8, 2% SOS, 
10% glycerol, and 0.1 M OTT. The samples were heated for 3 min in 
boiling water, applied to 7.5% SDS-PAGE gels, and subjected to elec-
t rophoresis. The gels were then stained, dried, and autoradiographs 
were made. 
Cryoglobulin-Containing Seru.m and Purifical.ion of Cryoglobulins 
Blood was obtained from 10 patients with mixed· cryoglobulinemia, 
who were previously found to have hepatitis B vil'US antigen, ant ibody, 
or both in their sera [8]. The clinical presentation of these patients was 
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characterized by purpuric lesions on their lower extremities, weakness 
and/ or renal disease. Hepatomegaly, or evidence of hepatic dysfunctio~ 
by laboratory examination, but with adeq uate clinical liver function 
was a lso fou nd in them [8). The purpuric lesions were diagnosed a~ 
cu taneous vascu litis histologically. 
Serum and EDTA plasma were separated at 37°C, and either used 
immediately or stored at -70°C. Cryoprecipitates were isolated from 
plasma samples by storing a 25 ml sample in a glass test-tube at 4 oc for 
24 hr. The samples were then centrifuged at 2,000 g for 20 min at 4°C 
and the supernatant fractions were discarded. The precipitates wer~ 
washed 3 t imes with ice-co ld steri le sa line and were t hen resuspended 
in saline at 37°C for 20 min. The undissolved contaminants were 
removed by centrifugation, and the cryoproteins in the supernatant 
fraction were reprecipitated by storage at 4 °C. T he concentration of 
t he cryoglobu lins was determined by measuring their optical density at 
E / 280 nm while they were in a solubilized form . The redissolved 
cryoprecipitates ~ere analyzed by Ouchterlony immunodiffusion using 
monospec1f1c ant1sera and were found to contain lgG and IgM. One 
cryoprecipitate contained trace amoun ts of lgA as well. No Clq, C3, or 
C4 were detected. 
RESULTS 
Complement-Component Levels in the Sera of Patients with 
Cryoglobulinemia 
Levels of C4, C2, and C3 were determined by quantitative 
h emolytic assays in the sera of 10 patients with mixed cryoglob-
ulinemia. Three patterns of complement activation were noted. 
The first pattern showed elevated or normal levels of C4, C2 
and C3 in 2 patients who had pUl'pura, skin ulcers, peripheral 
neuropathy, and mild renal disease. The second and most 
common pattern showed markedly decreased levels of C4, and 
moderately decreased or normal levels of C2 and C3. This was 
seen in 6 patients who had pUl'pura, peripheral neuropathy, and 
laboratory evidence of abnormal liver function. The third pat-
tern showed markedly depressed levels of C4, C2, and C3 in 
two patients who had purpura and severe renal disease. 
Activation of Complement in Normal Human Serum by 
Purified Human C1yoglobulins 
As shown in the Methods section, the patients' cryoglobulins 
consisted of IgG and IgM, and as such, one might expect them 
to activate serum complement in vitro. In order to compare 
their relative complement-fixing abilities, 0.5 ml samples of 
purified human cryoglobulin, at a final concentration of 1 mg/ 
ml, were incubated with 0.5 ml of normal human serum at 37°C 
for 60 min. The cryoglobulins we1·e then precipitated by incu-
bation at 0°C for 30 min, and the supernatants removed by 
centrifugation (2,000 g) at 4 °C for 20 min. The C4, C2, and C3 
levels were measUl'ed in the serum supernatant as well as in a 
control sample of the same serum incubated without cryoglob-
ulins. The results (Table I) demonstrate that with only one 
exception (patient 4), each of the cryoglobulins tested was able 
to activate C4 and C2 to a variable degree as evidenced by the 
reduced levels of hemolytic activity of C4 and C2. However, the 
cryoglobulins failed to activate C3 in every patient except one 
(patient 3), who had severe renal disease. 
In order to determine whether the lack of C3 utilization by 
these cryoglobulins was due to poor formation of the enzyme 
TABLE I. Uti lization of C4, C2 a.;td C3 in normal human senun 
following incubation. with purified human. cryoglobulin.s 
% Utilization(' 
Cryoglobulin patient 
C4 C2 C3 
1 86 25 0 
2 26 27 0 
3" 63 55 57 
4 20 0 0 
" Va lues are expressed in terms of % ut ilization reflecting the difference 
between those values obtained when normal human serum was incu-
bated either with or without cryoglobulins. 
& This patient presented with severe renal disease. 
COMPLEMENT ACTIVATION 329 
responsible for cleavage of the C3 molecule known as the 
classical pathway C.l_convertase, or C42, an attempt was made 
to generate this C42 enzyme complex with pUl'ified human 
cryoglobulin. One-half milliliter of cryoglobulin solubilized in 
GVB++ at a concentration of l mg/ ml was incubated with 0.02 
ml of highly purified Cl (6,600 units) at 30°C for 15 min, and 
then 0°C for 1'5 min. The cryoprecipitate was centrifuged, the 
supernatant saved for measurement of Cl, and the cryoprecip-
itate then washed twice in D-GVB++ to prevent CI dissociation. 
Finally, the solubilized cryoglobulins were incubated with 0.1 
ml of purified C4 (100,000 units), under the same conditions 
described above. Following precipitation and removal of the 
supernatant for measmement of C4, the cryoprecipitate was 
incubated at 37°C for 15 min with a mixture of C2 and C3 (100 
units each) , and the supernatant of this reaction mixture was 
assessed for residual C2 and C3 activity. As shown in Table II 
the cryoglobulins consumed 65% of the C1, 100% of the C4, 85% 
of the C2, and 86% of the C3. Thus, it may be concluded, that 
the failure of the cryoglobulins to activate C3 in whole serum 
was not due to an impaired formation of the classical pathway 
C3 convertase. 
Modulation of the C1yoglobulin -Induced CJ42 Enzyme by C4-
bp 
As previously reported, C4b, the cleavage product of CI 
action on C4, is degraded in the fluid phase by the serum 
enzyme C3b inactivator (C3b INA), only in the presence of a 
recently recognized serum protein, C4 binding protein C4-bp 
(31,32). In .addit ion, C4-Jw accelerat~s the natUl'al :l.eca~ of the 
thermolabile enzyme, C<l~. thus servmg as an unportant control 
mechanism of the function of this enzyme (18). Based on these 
observations, it seemed of interest to investigate the role that 
C4-bp might have as a control protein in the activation of 
complement by cryoglobulins. 
Cryoprecipitates carrying CI and C4b, (Cryo-C14 ), were pre-
pared as in the previous experiment. The cryoprecipitates were 
divided into two 0.5 ml samples each containing cryoglobulin at 
a final concentration of 1 mg/ ml. After redissolving the cry-
oprecipitates by warming them at 37°C, one sample was mixed 
with C2 and C3 (100 units each), and the other with C2 (100 
units), C3 (100 units) and C4-bp (0.16 mg). After 15 min of 
incubation at 30°C, the samples were centrifuged, and the 
residual C3 and C2 activitie2._were measured in the superna-
tants. As shown in Fig 1 the C42 enzyme, formed in th e presence 
of C4-bp utilized only 15% of the C3 added; whereas in the 
absence of C4-bp, 86% of the C3 was utilized. Similarly, only 
26% of the C2 added was utilized in the presence of C4-bp as 
compared to 85% utilization of C2 in its absence. 
Control of Complement Activation by C1yoglobulins in 
Normal Human Serum by C4-bp 
The pre~ious experiments clearly demonstrated that purified 
cryoglobuhns were capable of initiating the formation of the 
classical pathway C3 convertase when mixed with pUl'ified 
complement components. They also showed that C4-bp con-
trolled the assembly and function of this convertase. However 
the question remained as to whether the function of C4-bp i~ 
normal human serum was similar. This was studied in t he 
following experiment. Duplicate 0.5 ml samples of normal hu-
man. sera were depleted of their C4-bp by passage tru·ough a 
speCific tmmunoabsorbent column. One of these samples was 
TABLE II. Formation. of the C42 enzyme using purified 
cryoglobulins and purified complement components 
No. of Units C! C4 C2 
Input 6,600 26,500 100 
Residual 2,300 0 15 
% Utilization 65% 100% 35% 
C3 
72 
10 
86% 
330 HAYDEY, de ROJAS, AND GIGLI 
incubated with 0.5 ml of D-GVB ++, and the other with 0.5 rnl 
of solubilized cryoglobulin (final concentration 1 mg/ rnl). As 
controls, samples of the same normal human sera were passed 
through a column which did not contain the anti-C4-bp anti-
body, and these samples were then incubated with either D-
GVB++ or solubilized cryoglobulin as before. The cryoprecipi-
tates were removed by centrifugation and the serum superna-
tants analyzed for residual C3 activity. As shown in Fig 2, 
cryoglobulins incubated with normal serum failed to utilize C3 
whereas those incubated with serum depleted of C4-bp utilized 
71% of the C3 present. 
Cleavage of C4b Bound to Cryoglobulins by C4-bp and 
C3biNA 
These last experiments demonstrated that C4-bp controls the 
formation of t he C42 enzyme and t hus the utilization of C3. C4-
bp also functions as a co-factor in the proteolysis of C4b, when 
in the presence of another serum enzyme, the C3b inactivator 
c: 100 ® 0 ® 
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FIG 1. Modulation of cryoglobulin-induced Cl42 enzyme by C4-bp. 
Cryoglobulins carrying Cl and C4b were incubated with C2 and C3 
diluted either in buffer alone (panel A), or in buffer containing C4-bp 
(panel B). C2 and C3 activities were measured in these samples and 
compared with the same complement components incubated in the 
absence of cryoglobulins. 
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FIG 2. Control of complement activation by cryoglobulins in normal 
human serum by C4-bp. In the left panel cryoglobulins incubated with 
normal human serum (containing C4-bp) were unable to utilize C3. 
When incubated with normal hu man serum depleted of C4-bp, as 
depicted in the right panel, cryoglobulins were able to utilize 71% of the 
C3 present. No C3 consumption was observed in serum incubated with 
buffer alone. 
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FIG 3. Cleavage of C4b bound to cryoglobulins by C4-bp and 
C3biNA. Autoradiography was performed after SDS-PAGE of samples 
of cryoglobulin-C l4 prepared with 12"I-C4 and incubated with either D-
GVB++ (lrach 1), C4-bp (trach 2), C3blNA (lrach 3), or C3blNA and 
C4-bp (tra.ch 5). 12"I-C4 (trach 5), was used as the reference standard. 
Tra.ch 5 shows the a, {3 and y chains of native C4. Tra.chs I and 2 show 
the a', {3 , and y chains which characterize C4b. Tracks 3 and 4 show, in 
addition to the {3 and y chains of C4b, the fragments of cleavage of the 
a' chain, as evidenced by the appearance of the additional bands a'2 
(C4d) and a'4. The a'3 fragment is not seen in this preparation as it 
contains the least amount of radioactive !able, but its relative position 
has been indicated in the fi gure. 
(C3blNA) [31). In the next experiment, we examined whether 
C4-bp and C3biNA could change the structure of C4b bound to 
purified cyroglobulins. Cryoglobulin-Cl was prepared as in the 
previous experiment. It was incubated with 12"1-C4, centrifuged, 
and washed with D-GVB++ until no counts were found in the 
supernatant. The cryo 12"I-C4b was resuspended in 0.5 rnl of 
buffer and divided into four 0.1 ml samples. Each sample was 
incubated for 60 minutes at 37°C with 0.15 rnl of either D-
GVB++, C4-bp (0.08 mg), C3biNA (30 units), or both C4-bp and 
C3biNA. After washing, the solubilized cryoprecipitates were 
subjected to slab gel electrophoresis and then an autoradi-
ograph was made (Fig 3) . Gel samples 1 and 2, in which the 
cryo 12"1-C4b was incubated with either buffer, or C4-bp, showed 
3 chains, a', {3 and y which characterize activated C4 (C4b). 
Samples 3 and 4, those in which the cryo 1251-C4b was incubated 
with either C3biNA, or C3biNA and C4-bp together, showed 
further cleavage of the a' chains of C4b as evidenced by the 
appearance of the a'2 (C4d), a'3 a nd a' 4 fragments. These 
fragments correspond to those previously descr ibed by others 
as the cleavage products of the two control proteins [31). In 
addit ion, C3biNA alone can cleave bound C4b as reported by 
Gigli et al [18]. However, its ability to cleave C4b is enhanced 
by the presence of C4-bp, as shown by the greater intensity of 
the C4d band. 
DISCUSSION 
Studies of complement components in the sera of patients 
with mixed cryoglobulinemia have shown activation of the 
classical pathway [33-35]. However, the pattern of complement 
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activation that h as been found is unusua l in t hat the early 
complement components C1, C4, and C2, show variable degrees 
of utilization, but C3 levels are normal, except in patients with 
severe renal disease . Studies by Ruddy et al [17] of complement 
component synth esis and catabolism in th e sera of 3 patien ts 
with essential cryoglobulinemia suggested that the lowered 
levels of early complement components, C4 in particular, was 
due to theil· hyposynthesis and hypercatabolism. Tarantino et 
al [13] studied serum complement patterns in twenty-six pa-
tients with essential mixed cryoglobulinemia and found marked 
depression of C1q and C4 levels in t h e presence of normal C3 
levels. These authors also h ypothesized that the main m ech a-
nism responsible for these characteristic complement profiles 
was h yposynth esis of the early complemen t components. 
The fmdings of our studies on complement-component levels 
in the sera of 10 patients with mixed cryoglobulinemia are in 
agreement with other reports [33-35]. Most of our patients 
showed markedly decreased levels of C4, moderately decreased 
or normal levels of C2, and normal levels of C3. The same 
pattern of serum complement-component u tilization was ob-
served when cryoglobulins obtained from sera were pw·ified 
and then incubated with normal human serum (Table I) . This 
suggested that a mech anism other than complement hyposyn-
thesis could be involved. The possibility that cryoglobulins 
were unable to initiate the formation of the C42 enzyme, 
thereby preventing activation of C3, was investigated by incu-
bating purified cryoglobulins with p~ified complement com-
ponents in an attempt to form the C42 enzyme. The resultant 
consumption of C3 in this experiment (Table II) showed that 
cryoglobulins were in fact capable of initiating the formation of 
the C42 enzyme. Thus it was concluded that some other mech-
anism was responsible for the lack of C3 activation in normal 
serum. 
Recently, Gigli et al [18] described in normal human serum 
a previously unrecognized control protein of the C42 enzy~ 
th e C4-bp. This protein serves as a modulator of the 0!2 
enzyme by accelerating its decay. In addition, C4-bp acts as an 
accelerator of C3biNA, an enzyme which cleaves bound C4b to 
form fragments (C4c, C4d) which can no longer participate in 
the regeneration of the classical pathway convertase. 
In view of th e properties of t hese newly described serum 
proteins, several experiments were carried out to determine 
whether C4-bp might be responsible for the characteristic pat-
tern of complement component u t ilization seen in ow· patients 
with mixed cryoglobulinemia. 
The addition of C4-bp to th e purified complement compo-
nents used in formation of the C3 converting enzyme (C42) was 
shown to control the degree of C3 activation, as evidenced by 
th e decr eased consumption of C3 (Fig 1) . C4-bp was also shown 
to control the degr ee of C3 activation in norma l human serum 
incubated with pw·ified human cryoglobulins, in that removal 
of th e C4-bp from normal human serum prior to its incubation 
with purified huma n cryoglobulin, resulted in th e consumption 
of all complement components tested, including C3 (Fig 2) . 
However, C4-bp was not th e only control protein involved. 
As shown by experiments in which both C4-bp and C3biNA 
were incubated with C4b bound to cryoglobulins, C3biNA alone 
could cleave C4b to form C4c and C4d (Fig 3). Yet maximal 
cleavage of C4b required the presence of both C3biNA and C4-
bp. 
In conclusion, although the characteristic serum complement 
component abnormalities seen in patients with mixed cryoglob-
ulinemia may be related to complement hyposynth esis, our 
findings offer an alternative explanation. The consumption of 
the early serum complement components C1, C4, and C2 with 
the characteristic sparing of C3 can be attributed to th e action 
of a recently described control mechanism of the classical 
pathway C3 convertase. 
It is of interest to speculate whether there are differences in 
th e ch emical composition of c:.y_oglobulins that allow for a 
greater accessibility of C4b or C42 to th ese control proteins. 
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DISCUSSION 
PROVOST: Has C4 binding protein been found deposited in tissues at 
the site of lg and complement deposition, eg., lupus band test? 
GJGLI: V. Nussenzweig with Dr. Gallo has shown that the kidneys of 
patients with lupus have C4 binding protein deposited at the same site 
where one finds C4. 
JORDON: The complement profile of your patients is similar to 
patients with the so called acquired C1 esterase inhibitor deficiency 
who also have low C1, C4, and C2. These patients are also characterized 
by abnormal immunoglobulins (paraproteins). Were Cl esterase inhib-
itor levels in your patients reduced as they are in those patients? 
GIGLI: T he C1 inhibitor is usually normal or elevated. But I must 
add that these profiles are quite in teresting because it is basically what 
one sees in patients with het·editary angioedema. We have tested sera 
of these patients. We have added C4 to the serum after the C4 binding 
protein was removed and one gets a fantastic consumption of C3. 
JouooN: I am curious whether a similar mechanism might be in-
volved in those patients with the acquired "Cl esterase inhibi tor 
deficiency," all these patients had monoclonal proteins of some sort. 
Were the cryoglobulins you examined in this system all of the mixed 
cryoglobulins so that the antibody in that system is the lgM molecule 
and the antigen is the IgG mole<.:ule? Did you look at any of the 
monoclonal cryoglobulins? The one unique feature of these mixed 
cyroglobulins is that both the antigen and the antibody can provide 
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potential sites for interaction with the first component of complement; 
Could this be playing a role in this system? The reason I ask this is 
that one of my colleagues, Dr. William Aaron, has looked at the same 
system. H e took human immunoglobulin and interacted that with 
rabbit a nt ibody to the F(ab) area or with the second or third constant 
homology domain making complexes with comparable lattices. He 
found that they had different biological activities in terms of comple-
ment fixation or binding to the Fe receptor. 
GIGLI: The system in which we originally worked out the mechanisms 
of action of this protein is not homologous in any way to the cryoglob-
ulins. It was the hemolyt ic system where we have sheep erythrocytes 
and rabbit lgG . We plan to go back and look at the interaction with 
IgM. It may very well be that this is actually the consequence of the 
type of immunoglobulin involved in the reaction and that is the type of 
immunoglobulin which activates Cl and deposits C4 in a way that 
makes it most susceptible to this control mechanism. 
WuEPPER: What are the physical properties and subunit composit ion 
of the C4-bp? 
GIGLI: It is a glycoprotein with a sedimentation coefficient of about 
llS and consists of several disulfide bonded subunits of molecular 
weight 75,000 dal~ons. 
PROVOST: Can you absorb out the C4 binding protein from sera with 
rheumatoid facto r? 
GIGLI: When cryoglobulins or immune complexes are added to serum, 
C4-bp is incorporated into the complexes following complement acti-
vation. 
TIGALAAR: Would you please expand a bit on why you believe the 
pattern of complement consumption observed in these cases of mixed 
cryoglobulinemia is primarily due to a peculiar property of the cryoglob-
ulins rather than a perturbation of the regulatory system you have 
shown us. (e.g., perhaps a hyperactivity of C4-binding protein?) 
GIGLI: I am not saying that this control mechanism does not function 
in other modalities of complement activation. I am sure that whatever 
way that you activate complement, a competition between the control 
mechanism and the activating mechanism exists at all points. My work 
was made much easier by my background experience with the modu-
lation of the a lternate pathway which requires a different co-factor but 
everything else seems to be the same. In that case, it is clear that the 
surface that initiates the activation is what makes the converting 
enzyme more susceptible to the control proteins. I am sure that with 
C4-bp, the type of antibody which initiates the reaction is what makes 
the difference. 
